The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection
British Journal of Dermatology, 07/16/2012
Tsai TF et al. – Across five trials of ustekinumab–treated patients with psoriasis, no cases of latent tuberculosis infection (LTBI) reactivation were observed in patients receiving concomitant isoniazid (INH) prophylaxis for LTBI. INH prophylaxis was generally well tolerated by these patients with psoriasis.